Ampie Leonel, Choy Winward, Lamano Jonathan B, Kesavabhotla Kartik, Kaur Rajwant, Parsa Andrew T, Bloch Orin
Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Clin Neurol Neurosurg. 2016 Nov;150:143-151. doi: 10.1016/j.clineuro.2016.09.008. Epub 2016 Sep 19.
While preoperative embolization is often reserved for large and highly vascular tumors in order to minimize blood loss, its safety and efficacy in the treatment of hemangioblastomas (HB) is unclear. We present the largest systematic review focusing on the safety and outcome of preoperative embolization of intracranial HB.
To identify all cases of preoperative embolization for HB, a literature search was conducted via Medline (OVID and PubMed), Scopus, Embase, and Web of Science. Studies that were in English, included intracranial hemangioblastomas treated with preoperative embolization and provided sufficient disaggregated clinical data for each patient were included. Historical control patients with non-embolized intracranial HB undergoing resection were similarly identified.
A total of 111 patients that underwent preoperative embolization of HB prior to planned resection were identified. Patient age ranged from 12 to 72 years, with a cohort of 63% males and 36% females. Nine studies comprising 392 non-embolized patients were included as controls. Gross total resection was achieved in 83.7% of embolized and 95.6% of non-embolized patients. Intraoperative blood transfusion was required in 15.3% of embolized and 0.51% of non-embolized controls, while rates of post-operative hemorrhage were 8.4% and 1.6%, respectively. Complication rates from embolization were 11.7% and following consequent surgery were 20.7%.
Embolization did not increase rates of gross total resection, decrease estimated blood loss, or decrease incidence of complications. Not only does embolization fail to mitigate surgical risks, the embolization procedure itself carries significant risk for complications. Embolization should not be standard of care for intracranial HB.
虽然术前栓塞术通常用于大型且血管丰富的肿瘤,以尽量减少失血,但它在治疗血管母细胞瘤(HB)中的安全性和有效性尚不清楚。我们进行了规模最大的系统性综述,聚焦于颅内HB术前栓塞的安全性和治疗结果。
为了确定所有HB术前栓塞的病例,通过医学文献数据库(OVID和PubMed)、Scopus、Embase和科学网进行了文献检索。纳入英文研究,这些研究包括接受术前栓塞治疗的颅内血管母细胞瘤,并为每位患者提供了足够的分类临床数据。同样确定了接受切除手术的未栓塞颅内HB的历史对照患者。
共确定了111例在计划切除术前接受HB术前栓塞的患者。患者年龄在12至72岁之间,其中63%为男性,36%为女性。九项研究共纳入392例未栓塞患者作为对照。栓塞组患者的全切率为83.7%,未栓塞组为95.6%。栓塞组15.3%的患者术中需要输血,未栓塞对照组为0.51%,而术后出血率分别为8.4%和1.6%。栓塞的并发症发生率为11.7%,后续手术的并发症发生率为20.7%。
栓塞术并未提高全切率、减少估计失血量或降低并发症发生率。栓塞术不仅未能降低手术风险,其本身还存在显著的并发症风险。栓塞术不应成为颅内HB的标准治疗方法。